Sawicki Mark W 4
4 · Cryoport, Inc. · Filed Mar 13, 2023
Insider Transaction Report
Form 4
Cryoport, Inc.CYRX
Sawicki Mark W
Chief Scientific Officer
Transactions
- Sale
Common Stock
2023-03-13$20.14/sh−1,476$29,727→ 63,032 total - Exercise/Conversion
Restricted Stock Rights
2023-03-09−2,667→ 5,333 total→ Common Stock (2,667 underlying) - Exercise/Conversion
Common Stock
2023-03-09+2,667→ 64,508 total
Footnotes (3)
- [F1]Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock.
- [F2]Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
- [F3]The originally granted restricted stock rights vest in four equal annual installments beginning 3/9/2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2023.